Global Blood Therapeutics – Consensus Indicates Potential 81.2% Upside

Broker Ratings

Global Blood Therapeutics with ticker code (GBT) have now 19 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 102 and 31 with a mean TP of 61.68. With the stocks previous close at 34.04 this indicates there is a potential upside of 81.2%. The 50 day moving average now sits at 31.59 and the 200 day MA is 30.36. The market cap for the company is $2,269m. Find out more information at:

The potential market cap would be $4,112m based on the market concensus.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Global Blood Therapeutics, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics was incorporated in 2011 and is headquartered in South San Francisco, California.

Find more news, interviews, share price & company profile here for:

    Good news travels fast (but only if you make that happen). Share on:


      AIM All Share Index